Pilatus Raises $14M for First-in-Human Study of Anti-CD36 mAb
Pilatus; funding; anti-CD36 mAb; first-in-human study; biotech
Hikma announces CEO change and Board appointment
Hikma Pharmaceuticals; CEO change; Riad Mishlawi; Said Darwazah; Khalid Nabilsi; Board appointment; executive leadership; pharmaceuticals; London; 15 December 2025
Ankyra Therapeutics Appoints Sailaja Battula, PhD as Chief Scientific Officer
Ankyra Therapeutics; Sailaja Battula; CSO appointment; immuno-oncology; biotechnology
NeOnc Technologies Reports Updated Clinical Results for Intranasal NEO100
NeOnc Technologies; NTHI; NEO100; intranasal NEO100; updated clinical results; recurrent astrocytoma; WHO Grade III/IV; radiographic remission; overall survival; compassionate use; Phase 1/2a trial; CNS cancers
Immunome’s desmoid tumor drug varegacestat posts landmark Phase 3 results, setting up a potential challenge to Merck KGaA’s Ogsiveo
Immunome; varegacestat; desmoid tumors; Phase 3 RINGSIDE trial; gamma secretase inhibitor; Merck KGaA; Ogsiveo; progression-free survival; objective response rate; rare tumors; oncology; NDA filing
Aviceda’s AVD-104 misses Phase 2b primary endpoint vs Izervay but still headed to Phase 3
Aviceda; AVD-104; geographic atrophy; dry AMD; Phase 2b; SIGLEC trial; Izervay; avacincaptad pegol; clinical trial failure; Phase 3 prospects
Sanofi’s multiple sclerosis drug tolebrutinib flunks Phase 3 in PPMS and faces another FDA PDUFA delay
Sanofi; tolebrutinib; multiple sclerosis; primary progressive multiple sclerosis; PPMS; non-relapsing secondary progressive MS; nrSPMS; Phase 3 PERSEUS trial; PDUFA delay; FDA review; BTK inhibitor; clinical trial failure; regulatory setback
Scaling for a New Era: The Rise of Radiopharma
radiopharmaceuticals; radioligand therapy; oncology; precision oncology; targeted alpha therapy; Lutetium-177; Actinium-225; clinical trials; radiotheranostics; M&A; biotech funding; supply chain; infrastructure; CROs; companion diagnostics
Sobi Acquires Arthrosi Therapeutics for $950M Upfront in Gout Drug Deal
Sobi; Arthrosi Therapeutics; acquisition; gout; pozdeutinurad; AR882
‘Au Revoir TIGIT’: Gilead, Arcus Cut Gastro Cancer Drug After Late-Stage Failure
domvanalimab; TIGIT; Gilead Sciences; Arcus Biosciences; STAR-221; gastric cancer; esophageal cancer; zimberelimab; Opdivo (nivolumab); Phase 3 trial failure; overall survival; casdatifan; immuno-oncology; EDGE-Gastric